⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CVKD News
Cadrenal Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
globenewswire.com
CVKD
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
globenewswire.com
CVKD
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
globenewswire.com
CVKD